Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1917210 | 0.78 | MGAM (0.47) | ALDH1A1 | |
| SCHEMBL10397230 | 0.77 | PDE10A (0.57) | DDAH1POLBPDE10AKDM4ESMN1; SMN2 | |
| SCHEMBL7964155 | 0.77 | CHEK1 (0.58) | KMT2AMEN1DDAH1POLBPDE10A | |
| SCHEMBL9179087 | 0.77 | RAB9A (0.50) | KMT2AHPGDMEN1ALDH1A1PDE10A | |
| SCHEMBL1917492 | 0.77 | PSMB8 (0.49) | HPGDDDAH1POLBHTTKDM4E | |
| SCHEMBL9754832 | 0.77 | ALDH1A1 (0.46) | ALDH1A1DDAH1POLBPDE10AKDM4E | |
| SCHEMBL8818793 | 0.76 | ADORA3 (0.51) | — | |
| SCHEMBL15767180 | 0.75 | CHEK1 (0.41) | HPGDDDAH1POLBPDE10AHTT | |
| SCHEMBL9232152 | 0.75 | KDM4E (0.38) | KMT2AHPGDMEN1ALDH1A1DDAH1 | |
| SCHEMBL5110714 | 0.75 | KDM4C (0.42) | KMT2AHPGDMEN1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1988091-B1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-8242151-B2 | Tricyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1988091-A1 | TRICYCLIC COMPOUNDS | Kyowa Hakko Kogyo Co., Ltd (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-5527815-A | TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, AND HIGH INTRAOCULAR PRESSURE | KOTOBUKI SEIYAKU CO., LTD. (JP) | 1996-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | PPARG, PPARD, PPARA | KMT2A 1525/4885HPGD 1680/4885MEN1 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.